comparemela.com

Michelle Berrey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction

Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.

United statesMichelle berreyDrug administrationUniversity of miamiAmerican porphyria foundation cynthia levyUniversity of miami hospitalAmerican porphyria foundationCynthia levyLiver meetingAmerican associationLiver diseasesMiami hospitalIntercept announces new phaseShowing significant impactBezafibrate combinationMultiple key biomarkers

Intercept Pharmaceuticals, Inc (NASDAQ:ICPT) Q2 2023 Earnings Call Transcript

Operator: Hello, and thank you for standing by. Welcome to Intercept Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Linda richardsonJay olsonYasmeen rahimiEd arceEliana merlePiper sandlerAndrew saikJerry dursoRyan deschnerRaymond jamesMayank mamtaniNareg sagherianMichelle berreyMatthew dellatorreJon wollebenJerome durso

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Interim analysis of ongoing Phase 2 study shows combination of OCA 5-10 mg + bezafibrate 400 mg improved levels of multiple biochemical markers associated with clinical outcomes in PBC including ALP,. | June 7, 2023

United statesAntonio civitareseKaren prebleFrederik nevensAlexandre louvetLynda szczechNareg sagherianM michelle berreyCheng zouVaclav hejdaResearch developmentGlobenewswire incCompany on twitterIntercept pharmaceuticals incEuropean association for the studyGlobal corporate communications

Intercept Pharmaceuticals, Inc (NASDAQ:ICPT) Q4 2022 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Intercept Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Conference Call.

Nareg sagherianMichelle berreyJerry dursoMichelle berryAndrew saikLinda richardsonMayank mamtaniUs district court onMost profitable companiesIntercept pharmaceuticals incHealth photoIntercept pharmaceuticals fourth quarterIntercept pharmaceuticalsCall transcript marchFull yearExecutive director

Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022

Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis. | October 31, 2022

United statesSangeeta sawhneyPiotr milkiewiczMuhammady sheikhJames wasonJerome boursierStephena harrisonM michelle berreyJing liKaren prebleAndrewl masonJennifer callahanPhilipn newsomeMarco carboneTracy mayneC fiorella murillo perez

vimarsana © 2020. All Rights Reserved.